PS230005 Control-IQ 1.5 Post-Approval Study
Palo Alto (17 mi)Overseen byJordan Pinsker, MD
Age: < 18
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Recruiting
Sponsor: Tandem Diabetes Care, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the real-world setting.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Control-IQ Technology v1.5Experimental Treatment1 Intervention
Real-world use of Control-IQ technology v1.5 for 12 months.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Tandem Diabetes CareSan Diego, CA
Loading ...
Who is running the clinical trial?
Tandem Diabetes Care, Inc.Lead Sponsor
University of California, San DiegoCollaborator